Arsenic trioxide in the management of acute promyelocytic leukaemia

National Medical Journal of India

Volumn 14, Issue 4, 2001, Pages 215-222

  Mathews, Vikram ^a   Chandy, Mammen ^a   Srivastava, Alok ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; BUSULFAN;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; MALE; PATHOGENESIS; REVIEW; SCHOOL CHILD; SYPHILIS;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; ARSENICALS; CASPASES; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BCL-2; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; LEUKOCYTOSIS; MALE; MIDDLE AGED; OXIDES; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 0034859363     PISSN: 0970258X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Jolliffe DM. A history of the use of arsenicals in man. J R Soc Med 1993;86:287-9.
2. Thorburn AL. Paul Ehrlich: Pioneer of chemotherapy and cure by arsenic (1854-1915). Br J Vener Dis 1983;59:404-5.
3. Sears DA. History of the treatment of chronic myelocytic leukemia. Am J Med Sci 1988;296:85-6.
4. 4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR-alpha/PML proteins. Blood 1997;88:1052-61.
5. 3 exerts dose-dependent dual effects on APL cells. Blood 1997;89:3345-53.
6. 3) on acute promyelocytic leukemia cell line. Zhonghua Yixue Zazhi 1997;77:509-12.
7. Chen Z, Wang ZY, Chen SJ. Acute promyelocytic leukemia: Cellular and molecular basis of differentiation and apoptosis. Pharmacol Ther 1997;76:141-9.
8. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardasthi LJ, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998;339:1341-8.
9. Wang ZG, Rivi R, Delva L, Konig A, Scheinberg DA, Gambacorti-Passerini C, et al. Arsenic trioxide and melarsoprosol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RAR alpha independent manner. Blood 1998;92:1497-504.
10. Zhang P, Wang SY, Hu LH, Shi FD, Giu FQ, Hong GJ, et al. Arsenic trioxide treated 72 cases of acute promyelocytic leukemia. Chin J Hematol 1996;2:58.
11. 3) in the treatment of acute promyelocytic leukemia: II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89:3354.
12. Huang SY, Chang CS, Tang JL, Tien HF, Kuo TL, Huang SF, et al. Acute and chronic poisoning associated with treatment of acute promyelocytic leukemia. Br J Haematol 1998;103:1092-5.
13. Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999;94:3315-24.
14. Stone RM, Mayer RJ. The unique aspects of acute promyelocytic leukemia. J Clin Oncol 1990;8:1913-21.
15. Hillestead LK. Acute promyelocytic leukemia. Acta Medica Scand 1957;159: 189-94.
16. Rowley JD, Golomb HM, Dougherty C. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukemia. Lancet 1977;1:549-50.
17. Warrel RP Jr, de The H, Wang ZY, Degos L. Acute promyelocytic leukemia. N Engl J Med 1993;329:177-89.
18. Melnick A, Licht JD. Deconstructing a disease: RAR alpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999;93:3167-215.
19. Lin RJ, Egam DA, Evans RM. Molecular genetics of acute promyelocytic leukemia. Trends Genet 1999;15:179-84.
20. Leid M, Kastner P, Lyons R, Nakshatri H, Saunders M, Zacharcwski T, et al. Purification, cloning and RXR identity of the HeLa cell factor with which RAR heterodimerizes to bind target sequences efficiently. Cell 1992;68:377-95.
21. Heinzel T, Lavinsky RM, Mullen TM, Soderstrom M, Laherty CD, Forchia J, et al. A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature 1997;387:43-8.
22. Slack JL. Biology and treatment of acute progranulocytic leukemia. Curr Opin Hematol 1999;6:236-40.
23. Wang ZG, Delva L, Gaboli M, Rivi R, Georgio M, Cordon-Cardo C, et al. Role of PML in cell growth and the retinoic acid pathway. Science 1993;279:1547-51.
24. Guidez F, Ivans S, Zhu J, Soderstrom M, Waxman S, Zelent A. Reduced retinoic acid sensitivities of nuclear corepressor binding to PML and PLZF-RAR alpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood 1998;91:2634-42.
25. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-7.
26. Ferrucci PF, Grignani F, Pearson M, Fagioli M, Nicoletti I, Pellici G. Cell death induction by the acute promyelocytic leukemia-specific PML-RAR alpha fusion protein. Proc Natl Acad Sci USA 1997;94:10901-6.
27. Huang C, Ma WY, Li J, Dong Z. Arsenic induces apoptosis through a c-Jun NH2-terminal kinase-dependent, p53 independent pathway. Cancer Res 1999;59:3053-8.
28. Weis K, Rambaud S, Lavau C, Jansen J, Carvalho T, Carmo-Fonseca M, et al. Retinoic acid regulates aberrant localization of PML-RAR alpha in acute promyelocytic leukemia cells. Cell 1994;76:345-56.
29. Quignon F, De Bels F, Koken M, Feunteun J, Ameisen JC, de The H. PML induces a novel caspase-independent death process. Nat Genet 1998;20:259-65.
30. Monto Ho. Arsenic - New life for an old portion. Blood 1998;339:1389-91.
31. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999;15:2102-11.
32. Dai J, Jing Y, Hellinger N, Weinberg R, Waxman S. Mechanism of arsenic trioxide induced growth inhibition and apoptosis in malignant cells. Proc Am Assoc Cancer Res 1998;39:68-9.
33. Dai J, Weinberg RS, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999;93:268-77.
34. Westervelt P, Pollock J, Haugh J, Ley TJ, DiPersio JF. Response and toxicity associated with dose escalation of arsenic trioxide in the treatment of resistant acute promyelocytic leukemia (abstract). Blood 1997;Suppl 1:249b.
35. Sun HD, Ma L, Hu XC, Zhang TD. Ai-Lin I treated 32 cases of acute promyelocytic leukemia. Chin J Integrat Chin West Med 1992;12:170.
36. Bergstrom SK, Gillan E, Quinn JJ, Altman AJ. Arsenic trioxide in the treatment of a patient with multiple recurrent, ATRA resistant promyelocytic leukemia: A case report. J Pediatr Hematol Oncol 1998;20:545-7.
37. Spencer A, Firkin F. Arsenic trioxide treatment of relapsed acute promyelocytic leukemia: Initial Australian experience. Aust N Z J Med 1999;29:385-6.
38. Agis H, Weltermann A, Mitterbauer G, Thalhammer R, Edelhauser M, Seewann HL, et al. Successful treatment with arsenic trioxide of a patient with ATRA-resistant relapse of acute promyelocytic leukemia. Ann Hematol 1999;78:329-32.
39. Galimberti S, Papineschi F, Carmignani A, Testi R, Fazzi R, Petrini M. Arsenic and all-trans retinoic acid as induction therapy before autograft in a case of relapsed resistant secondary acute promyelocytic leukemia. Bone Marrow Transplant 1999;24:345-8.
40. Mathews V, Balasubramanian P, Shaji RV, George B, Chandy M, Srivastava A. Central nervous systemrelapse in apatient with acute promyelocytic leukemia treated with arsenic trioxide. Br J Haematol 2001;113:257-8.
41. Soignet SL, Frankel S, Tallman M, Douer D, Scheinberg DA, Dahlberg S, et al. Arsenic trioxide in relapsed acute promyelocytic leukemia (APL): The combined results and follow up from the US pilot and multicenter trials (abstract). Blood 2000;96:827a.
42. Evans G, Grimwade D, Prentice HG, Simpson N. Central nervous system relapse in acute promyelocytic leukemia in patients treated with all-trans retinoic acid. Br J Haematol 1997;98:437-9.
43. Di Noto R, Schiavone EM, Ferrara F, Manzo C, Lo Pardoc, Del Vecchio L. All-trans retinoic acid promotes a differential regulation of adhesion molecules on acute myeloid leukaemia blast cells. Br J Haematol 1994;88:247-55.
44. Brown DC, Tsuji H, Larson RS. All-trans retinoic acid regulates adhesion mechanism and transmigration of the acute promyelocytic leukaemia cell line NB-4 under physiologic flow. Br J Haematol 1999;107:86-98.
45. Zheng W, Perry DF, Nelson DL, Aposhian HV. Choroid plexus protects cerebrospinal fluid against toxic metals. FASEB J 1991;5:2188-93.
46. Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K, et al. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 2000;133: 881-5.
47. Unnikrishnan D, Dutcher JP, Varshneya N, Lucariello R, Api M, Gari S. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood 2001;97: 1514-16.
48. Frankel SR, Eardley A, Lauwers G, Weiss M, Warrel RP Jr. The "retinoic acid syndrome" in acute promyelocytic leukemia. Ann Intern Med 1992;117:292-6.
49. Camacho LH, Soignet SL, Chanel S, Ho R, Heller G, Scheinberg DA, et al. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J Clin Oncol 2000;18:2620-25.
50. Zhao CQ, Young MR, Diwan BA, Coogan TP, Waalkes MP. Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc Natl Acad Sci USA 1997;94:10907-12.
51. Hei TK, Liu SX, Waldren C. Mutagenicity of arsenic in mammalian cells: Role of reactive oxygen species. Proc Natl Acad Sci USA 1998;95:8103-7.
52. Cuzick J, Evans S, Gillman M, Prince Evans DA. Medicinal arsenic and internal malignancies. Br J Cancer 1982;45:904-11.
53. Gianni M, Koken MH, Chelbi-Alix MK, Benoit G, Lanotte M, Chen Z, et al. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic resistant NB4 cells. Blood 1998;91:4300-10.